Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia

Critical Care Medicine

Volumn 27, Issue 4, 1999, Pages 756-763

  Heller, Susanne ^a   Weber, Katrin ^a   Heller, Axel ^a   Urbaschek, Renate ^b   Koch, Thea ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bacteremia; Bacterial clearance; Endotoxemia; Escherichia coli; Flow cytometry; Hemorrhage; Infection; Organ colonization; Pentoxifylline; Respiratory burst

Indexed keywords

PENTOXIFYLLINE;

ARTERIAL GAS; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BLEEDING; BLOOD PRESSURE; CHINCHILLA; DISEASE SIMULATION; ENDOTOXEMIA; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; LACTATE BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RESPIRATORY BURST;

ANIMALS; BACTEREMIA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FREE RADICAL SCAVENGERS; GRANULOCYTES; HEMORRHAGE; INFUSIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; PENTOXIFYLLINE; PROSPECTIVE STUDIES; RABBITS; RANDOM ALLOCATION; RESPIRATORY BURST;

EID: 0032917414     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199904000-00031     Document Type: Article

References (46)

1. Koch T, Annuss C, Schiefer HG, et al: Impaired bacterial clearance after activation of the complement and coagulation systems. Shock 1997; 7:42-48
2. Koch T, Duncker HP, Axt R, et al: Effects of hemorrhage, hypoxia, and intravascular coagulation on bacterial clearance and translocation. Crit Care Med 1993; 21:1758-1764
3. Porter JM, Culter BS, Lee BY, et al: Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104:66-72
4. Nenci GG, Gresele P, Agnelli G, et al: Effect of pentoxifylline on platelet aggregation. Pharmatherapeutica 1981; 2:532-538
5. Silomon M, Pizanis A, Larsen R, et al: Pentoxifylline prevention of altered hepatocyte calcium regulation during hemorrhagic shock/resuscitation. Crit Care Med 1998; 26:494-500
6. Koch T, Neuhof H, Duncker HP, et al: Influence of a pentoxifylline-analogue on the granulocyte-mediated pulmonary mediator release and vascular reaction. Circ Shock 1993; 40:83-91
7. Sullivan GW. Carper HT, Novick WJ, et al: Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immunol 1988; 56:1722-1729
8. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31:171-181
9. Koch T, Duncker HP, Axt R, et al: Alterations of bacterial clearance induced by endotoxin and tumor necrosis factor. Infect Immunol 1993; 61:3143-3148
10. Thiel M, Bardenheuer H, Pöch G, et al: Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991; 180: 53-58
11. Josaki K, Contrino J, Kristie J, et al: Pentoxifylline-induced modulation of human leukocyte function in vitro. Am J Pathol 1990; 136:623-630
12. Zheng H, Crowley J, Chan JC, et al: Attenuation of LPS-induced neutrophil thromboxane B2 release and chemiluminescence. J Cell Physiol 1991; 146: 264-269
13. Currie MS, Rao KMK, Padmanabhan J, et al: Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990; 47: 244-250
14. Sandys GH: A new method of preventing swarming of Proteus sp. with a description of a new medium suitable for use in routine laboratory practice. J Med Lab Technol 1960; 17:224-233
15. Leijh PC, van den Barselaar MT, van Zwet TL, et al: Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. Immunology 1979; 37:453-465
16. Gelfand JA, Fauci AS, Green I, et al: A simple method for the determination of complement receptor-bearing mononuclear cells. J Immunol 1976; 116: 595-599
17. Emmendörffer A, Hecht M, Lohmann-Matthes M-L, et al: A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods 1990; 131:269-275
18. Baumgartner JD, Glauser MP, Mc Cutchan JA: Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985; 2:59-63
19. Calandra T, Glauser MP, Schellekens J, et al: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 1988; 158:312-319
20. Horgan MJ, Wright SD, Malik AB: Antibody against leukocyte integrin (CD18) prevents reperfusion-induced lung vascular injury. Am J Physiol 1990; 259:L315-L319
21. Vedder NB, Winn RK, Rice CL, et al: A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. J Clin Invest 1988; 81:939-944
22. Zhang H, Spapen H, Nguyen DC, et al: Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 1994; 266:H1746-H1754
23. Suter PM, Domenighetti G, Schaller M-D, et al: N-acetylcysteine enhances recovery from acute lung injury in man: A randomized double blind, placebo-controlled clinical study. Chest 1994; 105:190-194
24. Grisham MB, Hernandez LA, Granger DN: Adenosine inhibits ischemia reperfusion-induced leukocyte adherence and extravasation. Am J Physiol 1989; 257:H1334-H1339
25. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76:5-13
26. Nolte D, Lehr H-A, Messmer K: Adenosine inhibits postischemic leukocyte-endothelium interaction in postcapillary venules of the hamster. Am J Physiol 1991; 261:H651-H655
27. Niehörster M, Schönharting M, Wendel A: A novel xanthine derivative counteracting in vivo tumor necrosis factor a toxicity in mice. Circ Shock 1992; 37:270-273
28. Suter PM, Pittet JF, Masouye PH, et al: Xanthine derivatives pentoxifylline and HWA 138 attenuate cardiocirculatory and pulmonary failure secondary to endotoxin in sheep. Circ Shock 1991; 34:140-141
29. Thiel M, Bardenheuer H, Schlösser A, et al: Rolle von cAMP bei der Hemmung der Superoxidanionenproduktion humaner polymorphkerniger Leukozyten duch Adenosin und Pentoxifyllin. Anaesthesist 1992; 41:707-708
30. Bessler H, Gilgal R, Djaldetti M, et al: Effect of pentoxifylline on the phagocytic activity, cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986; 40:747-754
31. Freyburger G, Belloc F, Boisseau MR: Flow cytometry analysis of human neutrophils labeled with rhodamine phalloidin: Effect of pentoxifylline. Biorheology 1990; 27:445-448
32. Neuner P, Klosner G, Pourmojib M, et al: Pentoxifylline in vivo and in vitro down regulates the expression of the intercellular adhesion molecule on monocytes. Immunology 1997; 90:435-439
33. Endres S, Fülle HJ, Sinha B, et al: Synthesis of tumor necrosis factor is selectively suppressed by phosphodiesterase inhibitors. Immunology 1991; 72:56-60
34. Strieter RM, Remick DG, Ward PA, et al: Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155:1230-1236
35. Weithman KU: Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP. Gen Pharmacol 1983; 14:161-162
36. Hammerschmidt DE, Kotasek D, McCarthy, et al: Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988; 112:254-263
37. Bacher A, Mayer N, Klimscha W, et al: Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 1997; 25:795-800
38. Thiel M, Bardenheuer HJ: Medikamentöse Therapie der Sepsis. Anaesthesist 1994; 43:249-256
39. Farrukh JS, Gurtner GH, Michael JR: Pharmacological modification of pulmonary vascular injury: Possible role of cAMP. J Appl Physiol 1987; 62:47-54
40. Nilson CP, Crowley JJ, Morgan ME, et al: Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3,5-adenosine monophosphate. Am Rev Respir Dis 1988; 137:25-30
41. Lundblad R, Ekstrom P, Giercksky K-E: Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995; 3:210-215
42. Wang P, Ba ZF, Zhou M, et al: Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. Surgery 1993; 114:352-358
43. Mah MP, Aeberhard EE, Gilliam MB, et al: Effects of pentoxifylline on in vivo leukocyte function and clearance of group B streptococci from preterm rabbit lungs. Crit Care Med 1993; 21: 712-720
44. Zeni F, Pain P, Vindimian M, et al: Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock. Crit Care Med 1996; 24:207-214
45. Staudinger T, Presterl E, Graninger W, et al: Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 1996; 22:888-893
46. Wang P, Ba ZF, Morrison MH, et al: Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery 1992; 112:457-458